Expression of cross-tolerance to a wide range of conditions in a human lung cancer cell line after adaptation to nitric oxide
Open Access
- 22 September 2017
- journal article
- Published by IOS Press in Tumor Biology
- Vol. 39 (9)
- https://doi.org/10.1177/1010428317723778
Abstract
Previously, we have shown that A549, a human lung adenocarcinoma, can be adapted to nitric oxide (NO●). NO● is a nitrogen-based free radical that is synthesized by a family of enzymes known as nitric oxide synthases. NO● has been shown to be overexpressed in patient populations of different cancers. In addition, it has been observed that patients who express high levels of nitric oxide synthases tend to have poorer clinical outcomes than those with low levels of expression. The original cell line A549 (parent) and the adapted A549-HNO (high nitric oxide) cell line serve as a useful model system to investigate the role of NO● in tumor progression and prognosis. We have previously shown that the A549-HNO-adapted cells grow aggressively when compared to A549-parent cells. Furthermore, we have shown that the A549-HNO-adapted cells exhibit a higher percentage of cell viability when exposed to ultraviolet and X-ray radiation than the A549-parent cells. Cancer patients who develop resistance to one treatment often become resistant to other previously unencountered forms of treatment. This phenomenon is known as cross-tolerance. To determine whether NO● is a potential cross-tolerance causing agent, we have expanded our research by conducting parallel studies to a variety of other agents and conditions beyond radiation and ultraviolet exposure. We exposed both cell lines to varying levels of chemotherapeutic drugs (taxol and doxorubicin), temperature, pH, calcium chloride, cadmium chloride, copper chloride, sodium chloride, ferrous chloride, and sodium-R-lipoic acid. Our results show that the A549-HNO cells exhibit greater viability than the A549-parent cells when exposed to each of the various conditions. Therefore, NO● is one potential driving force that can make tumor cells exhibit cross-tolerance.Keywords
This publication has 48 references indexed in Scilit:
- Basic Mechanisms of Therapeutic Resistance to Radiation and Chemotherapy in Lung CancerThe Cancer Journal, 2013
- Detection of Impaired Homologous Recombination Repair in NSCLC Cells and TissuesJournal of Thoracic Oncology, 2013
- The Cancer Stem-Cell Hypothesis: Its Emerging Role in Lung Cancer Biology and Its Relevance for Future TherapyJournal of Thoracic Oncology, 2012
- Imaging hypoxia to improve radiotherapy outcomeNature Reviews Clinical Oncology, 2012
- Targeting Homologous Recombination Repair in CancerPublished by Elsevier BV ,2012
- Molecular mechanisms of cisplatin resistanceOncogene, 2011
- American Society of Clinical Oncology Clinical Practice Guideline Update on Chemotherapy for Stage IV Non–Small-Cell Lung CancerJournal of Clinical Oncology, 2009
- DNA repair pathways as targets for cancer therapyNature Reviews Cancer, 2008
- Introduction to Clinical Radiation BiologyHematology/Oncology Clinics of North America, 2006
- Tumor volume: a basic and specific response predictor in radiotherapyRadiotherapy and Oncology, 1998